Cargando…

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension

INTRODUCTION: Currently available endothelin receptor antagonists for treating pulmonary arterial hypertension block either the endothelin (ET) receptor A or both A and B receptors. Transition from one endothelin receptor antagonist to another may theoretically alter side-effects or efficacy. We rep...

Descripción completa

Detalles Bibliográficos
Autor principal:	Safdar, Zeenat
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064451/ https://www.ncbi.nlm.nih.gov/pubmed/21468170 http://dx.doi.org/10.2147/VHRM.S15026

Ejemplares similares

A review of sitaxsentan sodium in patients with pulmonary arterial hypertension
por: Waxman, Aaron B
Publicado: (2007)

Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes
por: Lepist, Eve-Irene, et al.
Publicado: (2014)

Ambrisentan for the treatment of pulmonary arterial hypertension
por: Casserly, Brian, et al.
Publicado: (2009)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

A review of pulmonary arterial hypertension: role of ambrisentan
por: Barst, Robyn J
Publicado: (2007)

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
por: Elshaboury, Soha M, et al.
Publicado: (2013)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases
por: Safdar, Zeenat, et al.
Publicado: (2021)

Open label study of ambrisentan in patients with exercise pulmonary hypertension
por: Segrera, Sergio A., et al.
Publicado: (2017)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022)

Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis
por: Li, Mengtao, et al.
Publicado: (2020)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study
por: Huo, Y., et al.
Publicado: (2016)

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients
por: Lan, Wei-Fang, et al.
Publicado: (2022)

Update on pulmonary hypertension complicating chronic obstructive pulmonary disease
por: Jyothula, Soma, et al.
Publicado: (2009)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Use of Extracorporeal Membrane Oxygenation in Postpartum Management of a Patient with Pulmonary Arterial Hypertension
por: Abid Memon, Humna, et al.
Publicado: (2018)

Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model
por: Lee, Hyeryon, et al.
Publicado: (2019)

Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension
por: Medrek, Sarah K., et al.
Publicado: (2017)

Chronic Thromboembolic Pulmonary Hypertension Medical Management
por: Logue, Ryan, et al.
Publicado: (2021)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Spironolactone in pulmonary arterial hypertension: results of a cross-over study
por: Safdar, Zeenat, et al.
Publicado: (2020)

Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice
por: Kataoka, Masaharu, et al.
Publicado: (2019)

A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years
por: Ivy, Dunbar, et al.
Publicado: (2020)

Ambrisentan-induced severe asymptomatic thrombocytopenia
por: Kigitovica, Dana, et al.
Publicado: (2020)

The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study
por: Sato, Takahiro, et al.
Publicado: (2017)

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia
por: Schroeder, Thies, et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled study to evaluate sildenafil, ambrisentan combination therapy in pulmonary hypertension, particularly of Eisenmenger syndrome
por: Mohammed, Shaadab, et al.
Publicado: (2021)

PReS-FINAL-2267: Successful treatment of pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) with combination therapy of sildenafil and ambrisentan: a case report
por: Yamaguchi, KI, et al.
Publicado: (2013)

Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
por: Li, Xinmei, et al.
Publicado: (2020)

A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care
por: Lee, Joshua D., et al.
Publicado: (2020)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
por: Kuwana, Masataka, et al.
Publicado: (2020)

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH
por: Bravo, Miren, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7vkgg205e4uf2s4dorej2jlrj0